Jasper Therapeutics Inc. Common Stock (JSPR)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn money, possess durable advantages, and sell below intrinsic value. Jasper fails the first test. In fiscal 2023, the year ended 2023-12-31, net income was -$64.5M; in fiscal 2024, the year ended 2024-12-31, it was -$71.3M; in fiscal 2025, the year ended 2025-12-31, it was -$75.8M. No revenue is reported in any filed period, so there is no moat to measure. In fiscal Q3 2025, the quarter ended 2025-09-30, net income was -$18.7M. More recently, fiscal Q1 2026 (ended 2026-03-31) showed -$1.2M and diluted EPS of -$0.04, while fiscal Q2 2026 (ended 2026-06-30) showed -$2.8M and diluted EPS of -$0.10. Smaller losses are encouraging, but they do not create a durable business. The financials are fragile: trailing free cash flow is -$60.3M, which is -365.6% of the $16.5M market cap at the close on 2026-10-13. FairStock's Altman Z-Score is -36.70 and Piotroski is 1/9. FairStock's P/B is 9.92 and ROE is -230.31%, so the market is paying a premium to book for a company destroying capital. D/E of 0.30 is not high, but cash burn is the real risk. Beta is 3.08, and the 52-week range of $0.31 to $2.69 shows violent speculation. FairStock assigns no Lynch category because losses occurred in each of the last four years. At $0.50, the price is not cheap on earnings; there are none. I would need clear cash runway, partnership validation, and a path to revenue before calling this an investment rather than a lottery ticket.

In plain English: Jasper Therapeutics is a clinical-stage biotech trying to develop experimental medicines for immune diseases and stem cell conditioning. It has no reported revenue and has lost money in each of the last four years, with heavy cash spending. At $0.50, the price looks very speculative rather than cheap, because the company's value depends on future trial results, not current profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer